Insider Trading activities at Map Pharmaceuticals, Inc. (MAPP)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Map Pharmaceuticals, Inc. (MAPP) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Map Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1401923.

Total stock buying since 2010: $31,380.
Total stock sales since 2010: $17,210,027.
Total stock option exercises since 2010: $1,608,283.

▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at *Map Pharmaceuticals, Inc.* (*MAPP*).
	Insider Buying		Insider Sales		Option Exercises
Year	Shares	Value	Shares	Value	Shares	Value
2013	0	$0	201,813	$5,004,039	218,895	$942,270
2012	0	$0	130,478	$2,055,005	64,753	$333,912
2011	2,000	$31,380	120,841	$7,652,033	141,596	$83,657
2010	0	$0	172,744	$2,498,950	172,744	$248,444

Table 2. Monthly summary of insider trading at *Map Pharmaceuticals, Inc.* (*MAPP*).
Trading Period	Insider Buying		Insider Sales		Option Exercises
year-month	Shares	Value	Shares	Value	Shares	Value
2013-02	0	$0	31,429	$785,339	30,000	$326,799
2013-01	0	$0	170,384	$4,218,700	188,895	$615,471
2012-11	0	$0	11,007	$168,801	11,007	$47,121
2012-06	0	$0	0	$0	1,125	$0
2012-04	0	$0	2,500	$35,947	2,500	$15,975
2012-03	0	$0	20,000	$350,000	20,000	$187,620
2012-02	0	$0	92,500	$1,438,178	12,500	$79,875
2012-01	0	$0	4,471	$62,079	17,621	$3,321
2011-12	0	$0	41,341	$6,393,708	30,000	$20,249
2011-09	0	$0	32,000	$492,288	32,000	$23,776
2011-08	0	$0	0	$0	26,250	$0
2011-07	0	$0	1,500	$23,938	1,500	$1,114
2011-06	0	$0	1,500	$25,453	1,500	$1,114
2011-05	0	$0	6,500	$108,179	6,500	$4,829
2011-04	0	$0	1,500	$21,063	1,500	$1,114
2011-03	2,000	$31,380	31,500	$506,755	37,346	$27,747
2011-02	0	$0	2,500	$38,677	2,500	$1,857
2011-01	0	$0	2,500	$41,972	2,500	$1,857
2010-12	0	$0	5,620	$85,412	5,620	$34,211
2010-10	0	$0	17,564	$273,979	17,564	$95,746
2010-09	0	$0	19,250	$261,248	19,250	$14,302
2010-08	0	$0	15,250	$197,250	15,250	$11,330
2010-07	0	$0	34,250	$426,213	34,250	$23,917
2010-06	0	$0	33,250	$479,073	33,250	$21,643

Table 3. Detailed insider trading at *Map Pharmaceuticals, Inc.* (*MAPP*)
Trade Date	Insider Name	Trade Type	Shares	Price ($)	Value ($)
2013-02-28	Gianakakos Anastasios (SVP, Chief Business Officer)	Sale	20,000	25.00	500,000
2013-02-28	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	20,000	10.37	207,399
2013-02-28	Henwood Geraldine (Director)	Sale	10,000	25.00	250,000
2013-02-28	Henwood Geraldine (Director)	Option Ex	10,000	11.94	119,400
2013-02-01	Kellerman Donald J (SVP,Clinical Dev & Med Affairs)	Sale	1,429	24.73	35,339
2013-01-26	Borland Scott (SVP, Neurology Franchise)	Sale	764	24.75	18,909
2013-01-26	Borland Scott (SVP, Neurology Franchise)	Option Ex	1,900	.00	0
2013-01-26	Armer Thomas A (Chief Scientific Officer)	Option Ex	2,250	.00	0
2013-01-26	Chai Christopher Y (SVP, Chief Financial Officer)	Option Ex	2,250	.00	0
2013-01-26	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	2,250	.00	0
2013-01-26	Friedman Charlene A (SVP, Gen Counsel & Sec)	Option Ex	2,250	.00	0
2013-01-26	Kellerman Donald J (SVP,Clinical Dev & Med Affairs)	Option Ex	2,250	.00	0
2013-01-25	Borland Scott (SVP, Neurology Franchise)	Option Ex	3,000	.00	0
2013-01-25	Armer Thomas A (Chief Scientific Officer)	Option Ex	2,750	.00	0
2013-01-25	Chai Christopher Y (SVP, Chief Financial Officer)	Option Ex	2,750	.00	0
2013-01-25	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	2,750	.00	0
2013-01-25	Friedman Charlene A (SVP, Gen Counsel & Sec)	Option Ex	2,750	.00	0
2013-01-25	Nelson Timothy S (President and CEO)	Option Ex	9,375	.00	0
2013-01-25	Kellerman Donald J (SVP,Clinical Dev & Med Affairs)	Option Ex	2,750	.00	0
2013-01-23	Armer Thomas A (Chief Scientific Officer)	Sale	59,620	24.76	1,476,191
2013-01-23	Armer Thomas A (Chief Scientific Officer)	Option Ex	39,620	6.39	253,171
2013-01-23	Gianakakos Anastasios (SVP, Chief Business Officer)	Sale	30,000	24.76	742,800
2013-01-23	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	30,000	10.37	311,100
2013-01-23	Nelson Timothy S (President and CEO)	Sale	80,000	24.76	1,980,800
2013-01-23	Nelson Timothy S (President and CEO)	Option Ex	80,000	.64	51,200
2012-11-23	Henwood Geraldine (Director)	Sale	5,240	15.00	78,600
2012-11-23	Henwood Geraldine (Director)	Option Ex	5,240	1.96	10,270
2012-11-01	Gianakakos Anastasios (SVP, Chief Business Officer)	Sale	5,767	15.64	90,201
2012-11-01	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	5,767	6.39	36,851
2012-06-07	Borland Scott (SVP, Neurology Franchise)	Option Ex	1,125	.00	0
2012-04-02	Gianakakos Anastasios (SVP, Chief Business Officer)	Sale	2,500	14.38	35,947
2012-04-02	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	2,500	6.39	15,975
2012-03-09	Gianakakos Anastasios (SVP, Chief Business Officer)	Sale	10,000	17.50	175,000
2012-03-09	Gianakakos Anastasios (SVP, Chief Business Officer)	Option Ex	10,000	6.39	63,900
2012-03-09	Friedman Charlene A (SVP, Gen Counsel & Sec)	Sale	10,000	17.50	175,000
2012-03-09	Friedman Charlene A (SVP, Gen Counsel & Sec)	Option Ex	10,000	12.37	123,720
2012-02-21	Gianakakos Anastasios (SVP & Chief Business Officer)	Sale	2,500	16.01	40,020
2012-02-21	Gianakakos Anastasios (SVP & Chief Business Officer)	Option Ex	2,500	6.39	15,975
2012-02-14	Armer Thomas A (Chief Scientific Officer)	Sale	30,999	15.62	484,142
2012-02-13	Armer Thomas A (Chief Scientific Officer)	Sale	2,800	16.00	44,800
2012-02-08	Armer Thomas A (Chief Scientific Officer)	Sale	26,201	16.00	419,216
2012-02-06	Armer Thomas A (Chief Scientific Officer)	Sale	19,868	15.00	298,020
2012-02-06	Gianakakos Anastasios (SVP & Chief Business Officer)	Sale	10,000	15.00	150,000
2012-02-06	Gianakakos Anastasios (SVP & Chief Business Officer)	Option Ex	10,000	6.39	63,900
2012-02-03	Armer Thomas A (Chief Scientific Officer)	Sale	132	15.00	1,980
2012-01-26	Borland Scott (SVP, Neurology Franchise)	Option Ex	1,900	.00	0
2012-01-26	Armer Thomas A (Chief Scientific Officer)	Option Ex	2,250	.00	0
2012-01-26	Chai Christopher Y (SVP & CFO)	Option Ex	2,250	.00	0
2012-01-26	Gianakakos Anastasios (SVP & Chief Business Officer)	Option Ex	2,250	.00	0
2012-01-26	Friedman Charlene A (SVP President, Gen Counsel&Sec)	Option Ex	2,250	.00	0
2012-01-26	Kellerman Donald J (SVP,Clinical Dev & Med Affairs)	Option Ex	2,250	.00	0
2012-01-19	Gianakakos Anastasios (SVP & Chief Business Officer)	Sale	4,471	13.88	62,079
2012-01-19	Gianakakos Anastasios (SVP & Chief Business Officer)	Option Ex	4,471	.74	3,321
2011-12-21	Nelson Timothy S (President and CEO)	Sale	6,638	14.53	96,416
2011-12-21	Nelson Timothy S (President and CEO)	Option Ex	6,638	.64	4,254
2011-12-20	Nelson Timothy S (President and CEO)	Sale	13,362	14.51	193,815
2011-12-20	Nelson Timothy S (President and CEO)	Option Ex	13,362	.64	8,565
2011-12-19	Armer Thomas A (See Remarks)	Sale	20,000	14.00	280,000
2011-12-12	Gianakakos Anastasios (SVP & Chief Bus Officer)	Sale	1,341	4,342.64	5,823,477
2011-12-12	Gianakakos Anastasios (SVP & Chief Bus Officer)	Option Ex	10,000	.74	7,430
2011-09-20	Chai Christopher Y (Chief Financial Officer)	Sale	32,000	15.38	492,288
2011-09-20	Chai Christopher Y (Chief Financial Officer)	Option Ex	32,000	.74	23,776
2011-08-04	Borland Scott (SVP, Neurology Franchise)	Option Ex	5,000	.00	0
2011-08-04	Nelson Timothy S (President and CEO)	Option Ex	10,000	.00	0
2011-08-04	Kellerman Donald J (SVP,Clinical Dev & Med Affairs)	Option Ex	11,250	.00	0
2011-07-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	1,500	15.96	23,938
2011-07-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	1,500	.74	1,114
2011-06-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	1,500	16.97	25,453
2011-06-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	1,500	.74	1,114
2011-05-09	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	5,000	17.00	85,000
2011-05-09	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	5,000	.74	3,715
2011-05-02	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	1,500	15.45	23,179
2011-05-02	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	1,500	.74	1,114
2011-04-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	1,500	14.04	21,063
2011-04-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	1,500	.74	1,114
2011-03-17	Armer Thomas A (Chief Scientific Officer)	Option Ex	35,846	.74	26,633
2011-03-11	Ward Scott R (Director)	Buy	2,000	15.69	31,380
2011-03-04	Armer Thomas A (Chief Scientific Officer)	Sale	30,000	16.10	482,970
2011-03-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	1,500	15.86	23,785
2011-03-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	1,500	.74	1,114
2011-02-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	2,500	15.47	38,677
2011-02-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	2,500	.74	1,857
2011-01-03	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	2,500	16.79	41,972
2011-01-03	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	2,500	.74	1,857
2010-12-20	Friedman Charlene A (VP President, Gen Counsel &Sec)	Sale	3,120	15.50	48,360
2010-12-20	Friedman Charlene A (VP President, Gen Counsel &Sec)	Option Ex	3,120	10.37	32,354
2010-12-15	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	2,500	14.82	37,052
2010-12-15	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	2,500	.74	1,857
2010-10-27	Friedman Charlene A (VP President, Gen Counsel &Sec)	Sale	7,800	15.53	121,095
2010-10-27	Friedman Charlene A (VP President, Gen Counsel &Sec)	Option Ex	7,800	10.37	80,886
2010-10-27	Henwood Geraldine (Director)	Sale	9,764	15.66	152,884
2010-10-27	Henwood Geraldine (Director)	Option Ex	9,764	1.52	14,860
2010-09-20	Chai Christopher Y (Chief Financial Officer)	Sale	16,000	14.05	224,816
2010-09-20	Chai Christopher Y (Chief Financial Officer)	Option Ex	16,000	.74	11,888
2010-09-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	3,250	11.21	36,432
2010-09-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	3,250	.74	2,414
2010-08-05	Henwood Geraldine (Director)	Sale	12,000	12.78	153,408
2010-08-05	Henwood Geraldine (Director)	Option Ex	12,000	.74	8,916
2010-08-02	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	3,250	13.49	43,842
2010-08-02	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	3,250	.74	2,414
2010-07-21	Chai Christopher Y (Chief Financial Officer)	Sale	8,000	13.00	104,000
2010-07-21	Chai Christopher Y (Chief Financial Officer)	Option Ex	8,000	.74	5,944
2010-07-20	Chai Christopher Y (Chief Financial Officer)	Sale	8,000	12.42	99,384
2010-07-20	Chai Christopher Y (Chief Financial Officer)	Option Ex	8,000	.74	5,944
2010-07-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	3,250	12.47	40,534
2010-07-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	3,250	.74	2,414
2010-07-01	Nelson Timothy S (President and CEO)	Sale	15,000	12.15	182,295
2010-07-01	Nelson Timothy S (President and CEO)	Option Ex	15,000	.64	9,615
2010-06-03	Nelson Timothy S (President and CEO)	Sale	3,480	14.16	49,294
2010-06-03	Nelson Timothy S (President and CEO)	Option Ex	3,480	.64	2,230
2010-06-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Sale	3,250	14.38	46,751
2010-06-01	Gianakakos Anastasios (SVP, Cor & Business Dev)	Option Ex	3,250	.74	2,414
2010-06-01	Nelson Timothy S (President and CEO)	Sale	26,520	14.44	383,028
2010-06-01	Nelson Timothy S (President and CEO)	Option Ex	26,520	.64	16,999
2010-05-20	Chai Christopher Y (Chief Financial Officer)	Sale	16,000	14.77	236,352
2010-05-20	Chai Christopher Y (Chief Financial Officer)	Option Ex	16,000	.74	11,888
2010-05-13	Friedman Charlene A (VP President, Gen Counsel &Sec)	Sale	1,560	17.07	26,633
2010-05-13	Friedman Charlene A (VP President, Gen Counsel &Sec)	Option Ex	1,560	10.37	16,177
2010-05-13	Nelson Timothy S (President and CEO)	Sale	30,000	17.09	512,790
2010-05-13	Nelson Timothy S (President and CEO)	Option Ex	30,000	.64	19,230

Insider trading activities including stock purchases, stock sales, and option exercises of MAPP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Map Pharmaceuticals, Inc. (symbol MAPP, CIK number 1401923) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month